Hong Kong Pharmaceuticals Stock News

Uni-President China Holdings shares have drifted lower over the past week and quarter, yet the latest half year earnings tell a more nuanced story. The stock closed at HK$7.47 on 6 August, with recent returns under pressure, while trailing 12 month earnings per share sit at ¥0.501. That supports a P/E of 12.8x, above both peer and Hong Kong food industry averages, even as the company carries a high 7.38% dividend yield that is not well covered by recent earnings. For long term investors, the...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) is back in focus after Chinese regulators accepted a new indication application for its TROP2-directed ADC sacituzumab tirumotecan in first-line triple-negative breast cancer. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The regulatory momentum around sacituzumab tirumotecan and SKB565 comes alongside a 26.81% year to date share price return and a very large 3 year total shareholder return of about 7x. This suggests...

The market has spent the past week edging away from Far East Horizon, with the stock down around 8% over seven days and still sitting near HK$6.53 despite trading on a single digit P/E close to peers and far below industry levels. Yet the H1 2026 numbers tell a more stubborn story of earnings resilience. Net income from ongoing operations for the trailing twelve months stands at roughly C¥3.9b and basic earnings per share sit near C¥0.84. The real question now is whether today’s cool reaction...

Cathay Pacific Airways stock has been grinding higher in recent weeks, yet the real story sits in the earnings tape. The airline now trades on a trailing P/E of 6.9x while carrying a 12 month net margin of 10.3%. That is unusually lean pricing for a flag carrier delivering double digit profitability. The headline from this half year is simple. Profitability held up and earnings over the last year rose, while the share price at HK$15.14 still reflects an airline investors are treating with...

Essex Bio-Technology just closed at HK$2.39, capping a 90 day slide of about 24%, yet the latest half year report tells a more nuanced story than the share chart suggests. The stock still sits on a P/E near 5x while the business continues to generate hundreds of millions of Hong Kong dollars in revenue. The real headline from this earnings release is margin pressure. Net profit margin now sits at 15.4%, down from 18.2% a year ago. This puts the quality of those low multiples under the...

In recent weeks, global markets have experienced mixed movements, with major U.S. indices like the S&P 500 and Nasdaq Composite advancing, while the S&P MidCap 400 saw declines amid ongoing volatility related to central bank policies and geopolitical tensions. As small-cap stocks navigate these turbulent waters, investors often seek opportunities in companies that demonstrate resilience through strong fundamentals and strategic insider action.

In July 2026, Meitu’s AI-powered brand Wink expanded its creative toolkit, integrating AI video and image enhancement, editing, and content cleanup into a single connected workflow aimed at creators, small businesses, ecommerce sellers, marketers, and everyday users. This move meaningfully broadens Meitu’s AI imaging ecosystem by turning Wink into a one-stop platform that can repurpose and upgrade existing visual assets, potentially deepening user engagement across both professional and...

As Asian markets navigate a landscape marked by global economic shifts and technological advancements, investors are increasingly drawn to companies that demonstrate robust growth potential and strong insider confidence. In this environment, stocks with high insider ownership are often seen as promising opportunities, reflecting the belief of those closest to the company in its future prospects.

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Insiders who acquired CN¥99.4m worth of China NT Pharma Group Company Limited's ( HKG:1011 ) stock at an average price...

The market seemed underwhelmed by last week's earnings announcement from Bosideng International Holdings Limited...

Golden Resources Development International Limited ( HKG:677 ) just reported healthy earnings but the stock price...

While China International Development Corporation Limited ( HKG:264 ) shareholders have had a good week with the stock...

SUNeVision Holdings Ltd. ( HKG:1686 ), might not be a large cap stock, but it saw a double-digit share price rise of...

The market seemed underwhelmed by last week's earnings announcement from Four Seas Mercantile Holdings Limited...

Yeebo (International Holdings) Limited's ( HKG:259 ) stock wasn't much affected by its recent lackluster earnings...

China International Capital (SEHK:3908) moved to expand its international footprint with the launch of an asset custody service in Hong Kong, unveiled at its inaugural Embark Salon on 30 July. See our latest analysis for China International Capital. At a share price of HK$22.1, China International Capital has a 1-day share price return of 2.50% and a year-to-date share price return of 9.51%. Its 1-year total shareholder return of 11.58% and 3-year total shareholder return of 33.05% point to...

Even though Asia Allied Infrastructure Holdings Limited's ( HKG:711 ) recent earnings release was robust, the market...

As we navigate the diverse landscape of Asian markets, investors are keenly observing how global economic shifts and regional developments influence market dynamics. Penny stocks, a term that may seem outdated but remains relevant, often refer to smaller or newer companies offering growth opportunities at lower price points. When these stocks are supported by strong financial health and solid fundamentals, they can present an appealing mix of affordability and potential upside for investors...

In late July 2026, Keymed Biosciences announced positive global Phase III results for CMG901 (sonesitatug vedotin, AZD0901) in CLDN18.2-positive advanced gastric and related cancers, alongside Breakthrough Therapy Designation in China for its bispecific antibody CM512 in chronic rhinosinusitis with nasal polyps. These developments highlight Keymed’s progress in both oncology and immunology, anchored by its AstraZeneca partnership and a growing late-stage pipeline of first-in-class or highly...

Harbour Centre Development entered this earnings season with a reputation as a deeply loss making stock that screens as cheap on discounted cash flow models. The share price at HK$4.55 has drifted only modestly in recent weeks, which suggests investors were waiting for a clearer profit story rather than trading the name aggressively. The headline from this half year result is simple. Revenue held near HK$705 million, yet the company still reported a net loss of HK$82 million and a basic loss...

The market has already marked Horizon Construction Development down over the past three months, yet today’s H1 2026 numbers pose a tougher question. The stock closed at HK$0.67 on 5 August after a flat week, while the headline is a construction group still grinding out profit on very slim economics. Net profit margin over the past year sits at just 1.6% and earnings are flattered by a one off gain of CN¥56.7m. For a stock trading on a 12.5x P/E, that mix of thin margins and non recurring...

Fortune Real Estate Investment Trust slipped to HK$4.74 by yesterday’s close, leaving the stock down about 6.5% over three months even after today’s H1 2026 earnings drop. The headline is not revenue, which sat around HK$1.65b over the past twelve months. The story is the profit hole that still has not closed. Fortune REIT remains loss making on a trailing basis. Analysts have published projections that indicate a possible swing back to positive earnings over the coming years. In the short...

Techtronic Industries just reminded investors why it carries a premium valuation. The stock came into the results with a trailing P/E of 25.6x and a strong 90 day return of 13.9%. After the print, the headline is simple: power tools and equipment demand supported record first half 2026 revenue of US$8.3b and net income of US$738m, with basic earnings per share of US$0.405. The gap investors now need to judge is clear. Profit momentum looks solid, while a rich valuation and expectations...